Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00431184 · ClinicalTrials.gov registry record · Phase 2
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
A Phase 2 study of Bipolar Disorder and Schizoaffective Disorder, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT00431184 is a Phase 2 study of Bipolar Disorder and Schizoaffective Disorder that has completed, run by Mclean Hospital. The registered enrollment target is 19 participants, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00431184, a Phase 2 study of Bipolar Disorder and Schizoaffective Disorder, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.
Conditions Studied
Interventions
- DRUG Lorazepam
- DRUG Pentazocine
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00431184
The ClinicalTrials.gov registry entry for NCT00431184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (94% lower). The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Lorazepam is the first listed.
NCT00431184 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00431184 about?
NCT00431184 is a clinical study titled "Effects of Pentazocine Versus Lorazepam on Manic Symptoms". Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.
What is the current status of trial NCT00431184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2007-01. Estimated completion is 2011-03.
What conditions does trial NCT00431184 study?
This clinical trial studies the following conditions: Bipolar Disorder, Schizoaffective Disorder, Mania, Manic Disorder, Manic State.
What interventions are being tested in trial NCT00431184?
The interventions under investigation include: Lorazepam (DRUG), Pentazocine (DRUG).
Who is sponsoring clinical trial NCT00431184?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00431184 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
RECRUITING · Phase 2
-
Correcting Circadian Rhythms to Breakthrough in Bipolar Disorder
RECRUITING · Phase 2
-
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
RECRUITING · Phase 2
-
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
RECRUITING · Phase 2
-
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
RECRUITING · Phase 2
-
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.